Enavate Sciences GP, LLC - 12 Sep 2024 Form 3 Insider Report for Zenas BioPharma, Inc. (ZBIO)

Role
10%+ Owner
Signature
Zebra Aggregator, LP, By: Enavate Sciences GP, LLC, its General Partner, By: /s/ James P. Boylan, Manager
Issuer symbol
ZBIO
Transactions as of
12 Sep 2024
Net transactions value
$0
Form type
3
Filing time
12 Sep 2024, 21:38:55 UTC
Next filing
18 Sep 2024

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
holding ZBIO Series B Preferred Stock 12 Sep 2024 Common Stock 1,206,353 By Zebra Aggregator, LP F1, F2
holding ZBIO Series C Preferred Stock 12 Sep 2024 Common Stock 1,672,653 By Zebra Aggregator, LP F1, F2
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Each share of Series B Preferred Stock and Series C Preferred Stock (collectively, the "Preferred Stock") is convertible into shares of Common Stock of the Issuer on an 8.6831-for-one basis without payment of further consideration. Upon the closing of the Issuer's initial public offering, the Preferred Stock will convert into the number of shares of Common Stock of the Issuer shown in column 3. The Preferred Stock has no expiration date.
F2 Shares are directly held by Zebra Aggregator, LP ("Zebra"). Enavate Sciences GP, LLC ("Enavate") is the general partner of Zebra and may be deemed to share voting and investment power with respect to the shares held by Zebra. Enavate disclaims beneficial ownership of these shares except to the extent of its pecuniary interest therein, and the inclusion of these shares in this report shall not be deemed an admission of beneficial ownership of the reported securities for purposes of Section 16 or for any other purpose.